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Background: Treatment for peripheral vascular disease (PVD) has advanced with medical, device, and biologic therapies, but the full portfolio of 
PVD clinical trials has not yet been characterized.
Methods: Using Medical Subject Headings (MeSH) terms and clinical condition terminology, we identified 698 PVD trials from 40,970 
interventional clinical trials registered with Clinicaltrials.gov (CT.gov) between October 2007 and September 2010. Each PVD trial was reviewed and 
classified according to a specific disease condition. Trial characteristics were compared against cardiology and other disease trials (Table).
Results: Of the PVD studies in CT.gov, 527 were peripheral arterial disease (PAD) studies and 194 were venous disease studies. They included aortic 
disease (9.7%), lower-extremity PAD (18.3%), acute stroke (17.3), prevention (11.7%), lower-extremity ulceration (12.2%), and venous disease (20.1%). 
PVD studies tended to be later-phase and larger compared with trials of other disease states (Table 1), were more likely to investigate devices, and were 
less likely to investigate behavioral interventions. Although they were more likely to have a DMC, they were more likely to be industry-lead.
Conclusion: Most PVD trials are randomized, middle- or late-phase, and more likely to be sponsored by industry. Further investigation of behavioral 
therapies and trials that are not sponsored by industry are needed to promote evidence-based practices and improve care for this vulnerable population. 
Study Characteristics PVD Cardiology Other
Studies, n 698 2068 38,204
Industry lead sponsor, % 44 29 38
Data monitoring committee, % 55 53 40
Randomized, % 71.2 76.6 68.4
Blinding, %
Open 51.8 52.3 56.0
Single-blind 11.5 15.3 10.9
Double-blind 36.7 32.4 33.0
Interventions, %
Drug 50.9 44.0 61.5
Device 30.8 25.3 8.0
Procedural 13.2 14.7 9.7
Behavioral 3.2 6.4 8.3
Biological 4.0 2.4 7.5
Other 10.2 12.3 12.5
Study phase, %
1 6.3 3.5 16.0
1/2 4.2 2.7 5.3
2 17.5 12.9 21.2
2/3 5.3 3.0 2.5
3 19.1 16.3 15.0
4 27.4 34.9 26.5
Follow-up, y*† 2.0 (1.2-3.0) 1.9 (1.0-2.8) 1.6 (0.8-2.7)
Enrollment
Patients enrolled*‡ 110 (49-270) 117 (50-316) 60 (30-169)
Studies completed enrollment, % 23 22 31
Studies terminated enrollment, % 3.4 3.1 2.0
Regional variation
North America 50.5 43.5 58.4
Europe 39.2 43.0 29.3
*median (IQR)
†Incorporates anticipated values for 71.6% of PVD, 75.4% of cardiology, and 66.7% of other studies that have not 
completed enrollment or updated their CT.gov record.
‡Incorporates anticipated values from 74.8% of PVD, 78.0% of cardiology, and 70.3% of other studies that have not 
completed enrollment or updated their CT.gov record.
